Zheng Z, Chen C, Jiang L, et al. Incidence and risk factors of gastrointestinal neuroendocrine neoplasm metastasis in liver, lung, bone, and brain: a population-based study. Cancer Med. 2019;8(17):7288–98.
Article PubMed PubMed Central CAS Google Scholar
Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LA, Ezzat S, de Herder WW, Klimstra DS, Papotti M, Asa SL. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol. 2022;33(1):115–54.
Article PubMed CAS Google Scholar
Yao JC, Hassan M, Phan A, et al. One hundred years after Carcinoid: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72.
Lamberti G, La Salvia A. Neuroendocrine tumors: challenges and Future perspectives. J Clin Med. 2022;11(15):4351.
Article PubMed PubMed Central Google Scholar
Rossi RE, Massironi S. The increasing incidence of neuroendocrine neoplasms worldwide: current knowledge and open issues. J Clin Med. 2022;11(13):3794.
Article PubMed PubMed Central Google Scholar
Das S, Dasari A, Epidemiology. Incidence, and prevalence of neuroendocrine neoplasms: are there global differences? Curr Oncol Rep. 2021;23(4):43.
Article PubMed PubMed Central Google Scholar
Simoneaux R. A look at the increasing incidence of neuroendocrine tumors. Oncol Times. 2020;42(6):1–4.
Massironi S, Franchina M, Ippolito D, Elisei F, Falco O, Maino C, Invernizzi P. Improvements and future perspective in diagnostic tools for neuroendocrine neoplasms. Expert Rev Endocrinol Metabolism. 2024;19(4):349–66.
Klimstra DS, Klöppel G, La Rosa S, Rindi GW. Classification of neuroendocrine neoplasms of the digestive system. In: Digestive system tumours: WHO classification of tumours, 5th ed., vol. 1. IARC Press; 2019 ( pp. 16–19).
La Rosa S, Uccella S. Classification of neuroendocrine neoplasms: lights and shadows. Reviews Endocr Metabolic Disorders. 2021;22(3):527–38.
Vinik AI, Chaya C. Clinical presentation and diagnosis of neuroendocrine tumors. Hematol Oncol Clin North Am. 2016;30(1):21–48.
Esposito I, Klöppel G, Esposito I, Kasajima A, La Rosa S, Dizdar L, Knoefe WT, Schott M, Dromain C, Villard N, Lena H. Neuroendocrine neoplasms of the digestive system. Gastrointestinal Oncology: A Critical Multidisciplinary Team Approach 2e. 2024 Jan 23:470–537.
Rizen EN, Phan AT. Neuroendocrine tumors: a relevant Clinical Update. Curr Oncol Rep. 2022;24(6):703–14.
Article PubMed CAS Google Scholar
Pirasteh A, Lovrec P, Bodei L. Imaging of neuroendocrine tumors: a pictorial review of the clinical value of different imaging modalities. Rev Endocr Metab Disord. 2021;22(3):539–52.
Modica R, Benevento E, Liccardi A, Cannavale G, Minotta R, DI Iasi G, Colao A. Recent advances and future challenges in the diagnosis of neuroendocrine neoplasms. Minerva Endocrinol (Torino). 2024;49(2):158–74. https://doi.org/10.23736/S2724-6507.23.04140-4. Epub 2024 Apr 16. PMID: 38625065.
de Celis Ferrari ACR, Glasberg J, Riechelmann RP. Carcinoid syndrome: an update on the pathophysiology and treatment. Clinics. 2018;73:e490s.
Article PubMed Central Google Scholar
Condron ME, Pommier SJ, Pommier RF. Continuous infusion of octreotide combined with perioperative octreotide bolus does not prevent intraoperative carcinoid crisis. Surgery. 2016;159(1):358–67.
Al-Toubah T, Strosberg J. Somatostatin Analogs and Interferon in the Treatment of Neuroendocrine Tumors. Neuroendocrine Tumours: Diagnosis and Management. 2024 Sep 3:619– 30.
Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224–33.
Abenavoli E, Linguanti F, Briganti V, et al. carcinogensTypical lung carcinoids: review of classification, radiological signs, and nuclear imaging findings. Clin Transl Imaging. 2020;8(2):79–94.
Papaxoinis G, Lamarca A, Quinn AM, Mansoor W, Nonaka D. Clinical and pathologic characteristics of pulmonary carcinoid tumors in central and peripheral locations. Endocr Pathol. 2018;29(3):259–68.
Article PubMed PubMed Central CAS Google Scholar
Ketai LH, Mohammed TH, Kirsch J, Kanne JP, Chung JH, Donnelly EF, et al. ACR appropriateness criteria hemoptysis. J Thorac Imaging. 2014;29:W19–22.
Larici AR, Franchi P, Occhipinti M, et al. Diagnosis and management of hemoptysis. Diagn Interv Radiol. 2014;20:299–309. https://doi.org/10.5152/dir.2014.13426.
Article PubMed PubMed Central Google Scholar
Olsen KM, Manouchehr-Pour S, Donnelly EF, Henry TS, Berry MF, Boiselle PM, Colletti PM, Harrison NE, Kuzniewski CT, Laroia AT, Maldonado F. ACR appropriateness criteria® hemoptysis. J Am Coll Radiol. 2020;17(5):S148–59.
Hofland J, Kaltsas G, de Herder WW. Advances in the diagnosis and management of well-differentiated neuroendocrine neoplasms. Endocr Rev. 2020;41(2):371–403.
Article PubMed PubMed Central Google Scholar
Danti G, Berti V, Abenavoli E, et al. Diagnostic imaging of typical lung carcinoids: relationship between MDCT, 111In-Octreoscan and 18F-FDG-PET imaging features with Ki-67 index. Radiol Med. 2020;125(8):715–29.
Santiago-Naranjo KC, Ilaiwy A. Pulmonary carcinoid presenting with persistent pneumothorax. BMJ Case Rep. 2019;12(11):e231083.
Article PubMed PubMed Central Google Scholar
Shah M, Duong B, Karnath B, Nishi S, Rasmussen P. Carcinoid Tumor Presenting as Hemoptysis and Elevated Diaphragm. Cureus 2023.
Jahangiri OS, Robbins JR, Nagaraju S. Cureus. Masquerading as Pneumonia: A Lung Neuroendocrine Tumor Case Report. 2023.
Baghdadi A, Ghadimi M, Mirpour S, et al. Imaging neuroendocrine tumors: characterizing the spectrum of radiographic findings. Surg Oncol. 2021;37:101529.
Nakazono T, Yamaguchi K, Egashira R, Mizuguchi M, Irie H. Anterior mediastinal lesions: CT and MRI features and differential diagnosis. Jpn J Radiol. 2021;39(2):101–17.
Maxwell JE, Naraev B, Halperin DM, Choti MA, Halfdanarson TR. Shifting paradigms in the pathophysiology and treatment of Carcinoid Crisis. Ann Surg Oncol. 2022;29(5):3072–84.
Derks JL, Rijnsburger N, Hermans BC, Moonen L, Hillen LM, von der Thüsen JH, den Bakker MA, van Suylen RJ, Speel EJ, Dingemans AM. Clinical-pathologic challenges in the classification of pulmonary neuroendocrine neoplasms and targets on the horizon for future clinical practice. J Thorac Oncol. 2021;16(10):1632–46.
Article PubMed CAS Google Scholar
Ackman JB, Chung JH, Walker CM, Bang TJ, Carter BW, Hobbs SB, Kandathil A, Lanuti M, Madan R, Moore WH, Shah SD. ACR appropriateness Criteria® imaging of mediastinal masses. J Am Coll Radiol. 2021;18(5):S37–51.
Phan AT, Öberg K, Choi J, Harrison LH Jr, Hassan MM, Strosberg JR, Krenning EP, Kocha W, Woltering EA, Maples WJ. NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus). Pancreas. 2010;39(6):784–98.
Shikhare SN. Imaging of thoracic malignancies. Thorac Imaging: Basic Adv. 2019;101:46.
Cattoni M, Vallières E, Brown LM, et al. Is there a role for traditional nuclear medicine imaging in the management of pulmonary carcinoid tumors. Eur J Cardiothorac Surg. 2017;51(5):874–9.
Koukouraki S, Strauss LG, Georgoulias V, Eisenhut M, Haberkorn U, Dimitrakopoulou-Strauss A. Comparison of the pharmacokinetics of 68 Ga-DOTATOC and [18 F] FDG in patients with metastatic neuroendocrine tumours scheduled for 90 Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging. 2006;33:1115–22.
留言 (0)